Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) is now available.
Biocytogen Pharmaceuticals has announced the progress of its proposed initial public offering of A Shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The company has submitted the necessary prospectus, but the completion of the share issue is subject to certain conditions. Stakeholders are advised to exercise caution as the offering may or may not be completed.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and commercialization of innovative drugs, particularly in the field of biotechnology.
Average Trading Volume: 446,410
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.14B
For detailed information about 2315 stock, go to TipRanks’ Stock Analysis page.